Home / News / India News / Article /
Covaxin effective against Delta Plus variant of Covid-19: ICMR Study
Updated On: 02 August, 2021 12:00 AM IST | New Delhi | PTI
Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial

A vial of Covaxin | File Pic
Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in biorxivby the Indian Council of Medical and Research (ICMR).
"Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19 naive individuals full doses of BBV152 vaccine, Covid-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the study said.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.

